Atozet (ezetimibe/atorvastatin) vs Ezetimibe/simvastatin (Vytorin)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: HMG-CoA reductase / NPC1L1 · full Atherosclerotic Cardiovascular Disease pipeline
Atozet (ezetimibe/atorvastatin)
Rights held by Organon and partners; US product discontinued
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Ezetimibe/simvastatin (Vytorin)
Marketed by Organon
NCT00202878 · Phase 3 · completed
The trial randomly assigned 18,144 participants to Vytorin or simvastatin, used triple blinding, and included an active comparator. Its primary clinical endpoint occurred in 32.72% of the Vytorin group versus 34.67% of the simvastatin group; the difference was statistically significant (hazard ratio 0.936, 95% CI 0.887–0.988; p=0.016).
Reported efficacy
Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Time to First Occurrence of Cardiovascular Death, Major Coronary Event, or Non-fatal Stroke (Kaplan-Meier Estimate of Percentage of Participants Experiencing a Qualifying Event) (Up to approximately 9 years): Ezetimibe/Simvastatin 32.72% (95% CI 31.63 to 33.85) vs Simvastatin 34.67% (95% CI 33.56 to 35.81) (met)
Result source: NCT00202878
Results for Atherosclerotic Cardiovascular Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Atozet (ezetimibe/atorvastatin) | Ezetimibe/simvastatin (Vytorin) |
|---|---|---|
| LDL-C, % change | -49.0% vs -27.8%vs AtorvastatinNCT057614441 other result
| -49.3% vs -38.0%vs AtorvastatinNCT004967303 other results
|
| Non-HDL-C, % change | —Not reported | —Not posted · NCT00110435 |
| ApoB, % change | —Not reported | —Not posted · NCT00110435 |
| Lp(a), % change | —Not reported | —Not posted · NCT00110435 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT00110435 |
LDL-C, % change
- Atozet (ezetimibe/atorvastatin)
- -49.0% vs -27.8%vs AtorvastatinNCT05761444
1 other result
- -50.4% vs -34.4% NCT05761444
- Ezetimibe/simvastatin (Vytorin)
- -49.3% vs -38.0%vs AtorvastatinNCT00496730
3 other results
- -44.7% vs -27.1% NCT00762164
- -53.6% vs -38.3% NCT00110435
- -57.6% vs -50.9% NCT00110435
Non-HDL-C, % change
- Atozet (ezetimibe/atorvastatin)
- —Not reported
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
ApoB, % change
- Atozet (ezetimibe/atorvastatin)
- —Not reported
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
Lp(a), % change
- Atozet (ezetimibe/atorvastatin)
- —Not reported
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
3-point MACE (% with event)
- Atozet (ezetimibe/atorvastatin)
- —Not reported
- Ezetimibe/simvastatin (Vytorin)
- —Not posted · NCT00110435
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Atozet (ezetimibe/atorvastatin): 4 of 4 rows · Ezetimibe/simvastatin (Vytorin): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Atozet (ezetimibe/atorvastatin) | Ezetimibe/simvastatin (Vytorin) |
|---|---|---|
| Dropout rate | 11.9% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 | 24.3%Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results—Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 4.6%10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 12.1%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence 17.6%10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 14.4% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Discontinued due to AEs | 3% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 | —Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results—Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 5.2%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence —10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 0.8% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Serious AEs | 6% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 | —Ezetimibe/Simvastatina NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 5 more results40.1%Ezetimide/Simvastatin NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 —10/20 mg NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 0.6%10/20 mg NCT00654628 · Phase 4 · registry result, not featured evidence 0%10/80 mg divided into 4 NCT00762164 · Phase 4 · registry result, not featured evidence 0% NCT00442897 · Phase 4 · registry result, not featured evidence |
| Most frequent reported AEs | alanine aminotransferase increased 1.5% alopecia 1.5% anaemia 1.5% NCT05761444 · Phase 4 · registry result, not featured evidence · Atherosclerotic Cardiovascular Disease · phase 4 | a arthralgia 11% myalgia 10.5% pain in extremity 10.5% NCT00202878 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 show 4 more results10/20 mg hypercholesterolaemia 4.8% hypertriglyceridaemia 3.2% abdominal pain upper 1.6% NCT00496730 · Phase 3 · Atherosclerotic Cardiovascular Disease · phase 3 10/20 mg myalgia 4% upper respiratory infection 4% increased creatine phosphokinase (cpk) 3.5% NCT00654628 · Phase 4 · registry result, not featured evidence 10/80 mg divided into 4 muscle pain-myalgia 11.8% NCT00762164 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 3.7% headache 1.9% transaminases increased 1.9% NCT00442897 · Phase 4 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Atozet (ezetimibe/atorvastatin)
show 1 more result
show 1 more result
Ezetimibe/simvastatin (Vytorin)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 1 further endpoint in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atozet (ezetimibe/atorvastatin)'s landscape · Ezetimibe/simvastatin (Vytorin)'s landscape